参考文献/References:
[1] De Santis C,Ma J,Bryan L,et al.Breast cancer sta-tistics,2013[J].CA Cancer J Clin,2014,64(1):52-62.
[2] 张柏林,张 倩,Sivasubramaniam PG,等.中国年轻乳腺癌发病危险因素-多中心十年回顾性研究[J].中国肿瘤,2015,24(12):1042-1047.
Zhang BL,Zhang Q,Sivasubramaniam PG,et al.The risk factors of breast cancer in young women in china:a multi-center ten-years retrospective study[J].Chinese Cancer,2015,24(12):1042-1047.
[3] Lin H,Lin D,Xiong XS.Roles of human papilloma-virus infection and stathmin in the pathogenesis of sinonasal inverted papilloma[J].Head Neck,2016,38(2):220-224.
[4] Ying L,Su D,Zhu J,et al.Genotyping of stathmin and its association with clinical factors and survival in patients with ovarian cancer[J].Oncol Lett,2013,5(4):1315-1320.
[5] Werner HM,Trovik J,Halle MK,et al.Stathmin protein level,a potentialpredictive marker for taxane treatment response in endometrial cancer[J].PLoS One,2014,9(2):e90141.
[6] Nie W,Xu MD,Gan L,et al.Overexpression of sta-thmin 1 is a poor prognostic biomarker in non-small cell lung cancer[J].Lab Invest,2015,95(1):56-64.
[7] Hemdan T,Linden M,Lind SB,et al.The prognostic value and therapeutictarget role of stathmin-1 in urinary bladder cancer[J].Br J Cancer,2014,111(6):1180-1187.
[8] Miceli C,Tejada A,Castaneda A,et al.Cell cycle inhibition therapy that targets stathmin in in vitro and in vivo models of breast cancer[J].CancerGene Ther,2013,20(5):298-307.
[9] Liu X,Liu H,Liang J,et al.Stathmin is a potential molecular marker and target for the treatment of gastric cancer[J].Int J Clin Exp Med,2015,8(4):6502-6509.
[10] Berton S,Pellizzari I,Fabris L,et al.Genetic characterization of p27(kip1)and stathmin in controlling cell proliferation in vivo[J].CellCycle,2014,13(19):3100-3111.
[11] Lu Y, Liu C, Xu YF,et al.Stathmin destabilizing microtubule dynamicspromotes malignant potential in cancer cells by epithelial-mesenchymal transition[J].Hepatobiliary Pancreat Dis Int,2014,13(4):386-394.
[12] Allen MM,Douds JJ,Liang SX,et al.An immunohistochemical analysis ofstathmin 1 expression in uterine smooth muscle tumors:differential expression in leiomyosarcomas and leiomyomas[J].Int J Clin Exp Pathol,2015,8(3):2795-2801.
相似文献/References:
[1]张红雨,马兴璇.联合检测D-二聚体和CA153在乳腺癌诊治中的临床意义[J].现代检验医学杂志,2015,30(02):137.[doi:10.3969/j.issn.1671-7414.2015.02.043]
[2]王媛媛,艾克东,寇建锋.热休克蛋白70-hom基因+2437T/C多态性与乳腺癌易感性的相关性研究[J].现代检验医学杂志,2017,32(06):125.[doi:10.3969/j.issn.1671-7414.2017.06.001]
WANG Yuan-yuan,AI Ke-dong,KOU Jian-feng.Association between Polymorphism of Heat Shock Protein 70-hom
Gene +2437T/C and Susceptibility to Breast Cancer[J].Journal of Modern Laboratory Medicine,2017,32(05):125.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[3]洪宏,袁建芬,喻海忠.血清miR-765和CA153联合检测对乳腺癌的诊断价值[J].现代检验医学杂志,2018,33(03):92.[doi:10.3969/j.issn.1671-7414.2018.03.023]
HONG Hong,YUAN Jian-fen,YU Hai-zhong.Diagnostic Value of Combined Detection of Serum miR-765
and CA153 in Breast Cancer[J].Journal of Modern Laboratory Medicine,2018,33(05):92.[doi:10.3969/j.issn.1671-7414.2018.03.023]
[4]洪 宏,袁建芬,喻海忠.乳腺癌患者血清miR-765,miR-200b水平检测及与临床病理学相关研究[J].现代检验医学杂志,2018,33(06):55.[doi:10.3969/j.issn.1671-7414.2018.06.014]
HONG Hong,YUAN Jian-fen,YU Hai-zhong.Detection of Serum miR-765 and miR-200b Levels in Breast Cancer Patients and Its Correlation with Clinicopathology[J].Journal of Modern Laboratory Medicine,2018,33(05):55.[doi:10.3969/j.issn.1671-7414.2018.06.014]
[5]万 军.血清肿瘤标志物CA153,CA125,CEA和HER-2联合检测在乳腺癌诊断中的价值[J].现代检验医学杂志,2018,33(06):119.[doi:10.3969/j.issn.1671-7414.2018.06.031]
WAN Jun.Value of Combined Detection of Tumor Markers CA153,CA125,CEA and HER-2 in the Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2018,33(05):119.[doi:10.3969/j.issn.1671-7414.2018.06.031]
[6]靳庆娥,乌姗娜,张亚鑫,等.血清糖化血红蛋白和CA15-3水平检测与女性乳腺癌发病风险的相关性研究[J].现代检验医学杂志,2019,34(04):143.[doi:10.3969/j.issn.1671-7414.2019.04.035]
JIN Qing-e,WU Shan-na,ZHANG Ya-xin,et al.Relationship of Glycosylated Hemoglobin A1c
and Tumor Marker CA15-3 Levels in Serum
with Breast Cancer Susceptibility in Women of Beijing Area[J].Journal of Modern Laboratory Medicine,2019,34(05):143.[doi:10.3969/j.issn.1671-7414.2019.04.035]